» Our Services » In Silico Clinical Trials

Anaxomics' TPMS technology offers virtual experimentation for in silico clinical trials, making them faster, more economic and yielding more insightful results.

Anaxomics brings the power of systems biology to clinical trials.

In silico Clinical Trials (ISCT) are computer simulations of clinical trials. They are valuable for:

  • Optimizing clinical trial design
  • Studying drug effects in underrepresented subpopulations in clinical trials
  • Identifying biomarkers to monitor in clinical trials
  • Reducing the time, costs, and risks of trials.
For those reasons, regulatory agencies are promoting the use of computer modeling and simulation to support clinical trials and improve efficiency.


What does Anaxomics offer?

Anaxomics' ISCT methodology relies on a quantitative systems pharmacology (QSP) approach, which combines physiologically-based pharmacokinetic (PBPK) modeling with systems biology and AI-based modeling Therapeutic Performance Mapping System (TPMS). This enables the capture of drug response in virtual patient populations with individual and tissue-specific predictions, allowing for realistic simulations of human population behavior in silico.

Anaxomics' proprietary TPMS technology integrates biological, pharmaceutical and medical data into systems biology models to realistically simulate in silico the behavior of human populations. While classical system biology approaches rely on the statistical assessment of clinical variables, TPMS evaluates the therapeutic response in a more global manner, analyzing clinical trial in the context of human physiology, tracking the deep metabolic implications. This holistic approach holds the potential to generate mechanistic hypothesis for clinical observations.

ISCT protocol overview.

The protocol is divided into three main stages:

  • Phase I, including trial design and information compilation
  • Phase II, comprising mathematical modelling
  • Phase III, consisting of data analysis according to the trial design.


PBPK: Physiologically based pharmacokinetic; QSP: Quantitative systems biology.


  • Gutiérrez-Casares, J. R., C. Segú-Vergés, J. Sabate Chueca, T. Pozo-Rubio, M. Coma, C. Montoto and J. Quintero (2023). In silico evaluation of the role of lisdexamfetamine on attention-deficit/hyperactivity disorder common psychiatric comorbidities: mechanistic insights on binge eating disorder and depression.
    Front Neurosci. 17: p. 1118253.
    DOI: 10.3389/fnins.2023.1118253
  • Coto-Segura, P., C. Segú-Vergés, A. Martorell, D. Moreno-Ramírez, G. Jorba, V. Junet, F. Guerri, X. Daura, B. Oliva, C. Cara, O. Suárez-Magdalena, S. Abraham and J. M. Mas (2023). A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis.
    Front Immunol. 14: p. 1212981. 2.
    DOI: 10.3389/fimmu.2023.1212981
  • Gutiérrez-Casares, JR., J. Quintero, G. Jorba, V. Junet, V. Martínez, T. Pozo-Rubio, B. Oliva, X. Daura, JM. Mas and C. Montoto (2021). Methods to Develop an in silico Clinical Trial: Computational Head-to-Head Comparison of Lisdexamfetamine and Methylphenidate.
    Frontiers in Psychiatry. 12(1902).
    DOI: 10.3389/fpsyt.2021.741170
  • Gutiérrez-Casares, JR., J. Quintero, C. Segú-Vergés, P. Rodríguez, T. Pozo-Rubio, M. Coma and C. Montoto (2023). In silico clinical trial evaluating lisdexamfetamine's and methylphenidate's mechanism of action computational models in an attention-deficit/hyperactivity disorder virtual patients' population.
    Frontiers in Psychiatry. 14:939650.
    DOI: 10.3389/fpsyt.2023.939650

Contact Us